These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28904090)

  • 1. HIV-related cognitive decline despite viral suppression and complex confounds in American women.
    Cysique LA; Becker JT
    Neurology; 2017 Oct; 89(15):1540-1541. PubMed ID: 28904090
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to systemic HIV viral load suppression correlates with psychomotor speed performance.
    Sacktor N; Skolasky RL; Tarwater PM; McArthur JC; Selnes OA; Becker J; Cohen B; Visscher B; Miller EN;
    Neurology; 2003 Aug; 61(4):567-9. PubMed ID: 12939443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropharmacology.
    Winston A; Manji H
    Handb Clin Neurol; 2018; 152():55-64. PubMed ID: 29604984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive rebound with HAART regimen in HIV/AIDS greatly adds to patient's quality of life.
    Griffin PT; LaPlante A
    HIV Clin; 2012; 24(4):1-4. PubMed ID: 23259172
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive Impairment and Persistent CNS Injury in Treated HIV.
    Chan P; Hellmuth J; Spudich S; Valcour V
    Curr HIV/AIDS Rep; 2016 Aug; 13(4):209-17. PubMed ID: 27188299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary trends in HIV-associated neurocognitive disorders in Ghana.
    Sarfo FS; Kyem G; Asibey SO; Tagge R; Ovbiagele B
    Clin Neurol Neurosurg; 2021 Nov; 210():107003. PubMed ID: 34715557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and age do not substantially interact in HIV-associated neurocognitive impairment.
    Cysique LA; Maruff P; Bain MP; Wright E; Brew BJ
    J Neuropsychiatry Clin Neurosci; 2011; 23(1):83-9. PubMed ID: 21304143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-associated dementia in the era of highly active antiretroviral therapy (HAART).
    Xia C; Luo D; Yu X; Jiang S; Liu S
    Microbes Infect; 2011 May; 13(5):419-25. PubMed ID: 21262373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV infection 2002. Progress and limits].
    Delfraissy JF
    Rev Med Interne; 2002 Dec; 23 Suppl 5():529s-531s. PubMed ID: 12701242
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV infection and dementia in older adults.
    Valcour V; Paul R
    Clin Infect Dis; 2006 May; 42(10):1449-54. PubMed ID: 16619159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of anti-HIV-1 chemotherapy in Japan.
    Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
    [No Abstract]   [Full Text] [Related]  

  • 14. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Neurocognitive Performance and Mortality in HIV: Assessing the Prognostic Value of the HIV-Dementia Scale.
    Banerjee N; McIntosh RC; Ironson G
    AIDS Behav; 2019 Dec; 23(12):3482-3492. PubMed ID: 30820848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of cerebrospinal fluid/plasma HIV-RNA discordance with neurocognitive impairment.
    Cárdenas G; López-González M; Monzón-Falconi JF; Soto-Hernández JL; Perales-Martínez D; López-Vejar C
    Natl Med J India; 2015; 28(5):228-32. PubMed ID: 27132951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5th French-speaking conference on HIV/AIDS (Casablanca, 28-31 March 2010)].
    Milleliri JM; Goudjo A
    Med Trop (Mars); 2010 Jun; 70(3):226-8. PubMed ID: 20734588
    [No Abstract]   [Full Text] [Related]  

  • 19. Psychiatric disorders and HIV infection: impact on one another.
    Lyketsos CG; Federman EB
    Epidemiol Rev; 1995; 17(1):152-64. PubMed ID: 8521933
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV in adolescents: what we know and what we need to know.
    Benton TD; Ifeagwu JA
    Curr Psychiatry Rep; 2008 Apr; 10(2):109-15. PubMed ID: 18474200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.